Результати пошуку - Myron S. Czuczman

Уточнити результати
  1. 1
    Use of rituximab, the new FDA-approved antibody

    Use of rituximab, the new FDA-approved antibody за авторством Gail A. Leget, Myron S. Czuczman

    Опубліковано 1998
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

    Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression за авторством Scott H. Olejniczak, Francisco J. Hernandez‐Ilizaliturri, James L. Clements, Myron S. Czuczman

    Опубліковано 2008
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

    Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up за авторством Myron S. Czuczman, Robin Weaver, Baha Alkuzweny, Judy Berlfein, Antonio J Grillo-López

    Опубліковано 2004
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma

    Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma за авторством Ping‐Chiao Tsai, Francisco J. Hernandez‐Ilizaliturri, Naveen Bangia, Scott H. Olejniczak, Myron S. Czuczman

    Опубліковано 2012
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice

    Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice за авторством Yaya Chu, Jessica Hochberg, Ashlin Yahr, Janet Ayello, Carmella van de Ven, Matthew J. Barth, Myron S. Czuczman, Mitchell S. Cairo

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab <i>in vivo</i>

    Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituxima... за авторством Nishitha Reddy, Francisco J. Hernandez‐Ilizaliturri, George Deeb, Mark S. Roth, Mary Vaughn, Joy Knight, Paul K. Wallace, Myron S. Czuczman

    Опубліковано 2007
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy

    Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy за авторством Myron S. Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, Stephen Revell, Katie D. Vo, Arturo Molina

    Опубліковано 2007
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-re... за авторством Aradhana Awasthi, Janet Ayello, Carmella van de Ven, Mona Elmacken, Anthony Sabulski, Matthew J. Barth, Myron S. Czuczman, Humayun Islam, Christian Klein, Mitchell S. Cairo

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

    Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody за авторством David M. Goldenberg, Edmund A. Rossi, Rhona Stein, Thomas M. Cardillo, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri, Hans J. Hansen, Chien‐Hsing Chang

    Опубліковано 2008
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents

    Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents за авторством Sarah Frys, Zachary Simons, Qiang Hu, Matthew J. Barth, Juan Gu, Cory Mavis, Joseph J. Skitzki, Song Liu, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri

    Опубліковано 2015
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

    Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development за авторством Juan Gu, Anil Singh, Kai Xue, Cory Mavis, Matthew J. Barth, Vivek Yanamadala, Peter Lenz, Michael Grau, Georg Lenz, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma

    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma за авторством Myron S. Czuczman, Georg Heß, Ole Gadeberg, Lars Møller Pedersen, Nancy Goldstein, Ira Gupta, Roxanne C. Jewell, Thomas S. Lin, Steen Lisby, Claus Strange, Kristian Windfeld, Andreas Viardot

    Опубліковано 2012
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

    Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma за авторством Kieron Dunleavy, Stefania Pittaluga, Myron S. Czuczman, Sandeep S. Davé, George W. Wright, Nicole Grant, Margaret Shovlin, Elaine S. Jaffe, John E. Janik, Louis M. Staudt, Wyndham H. Wilson

    Опубліковано 2009
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) за авторством John P. Leonard, Sin‐Ho Jung, Jeffrey L. Johnson, Brandelyn N. Pitcher, Nancy L. Bartlett, Kristie A. Blum, Myron S. Czuczman, Jeffrey K. Giguere, Bruce D. Cheson

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response

    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response за авторством Asher Chanan‐Khan, Kena C. Miller, David Lawrence, Swaminathan P. Iyer, Austin Miller, Francisco Hernandez‐Illatazurri, Myron S. Czuczman, Paul K. Wallace, Jerome B. Zeldis, Kelvin H. Lee

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network

    Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network за авторством Ann S. LaCasce, Michelle E. Kho, Jonathan W. Friedberg, Joyce C. Niland, Gregory A. Abel, Maria Alma Rodriguez, Myron S. Czuczman, Michael Millenson, Andrew D. Zelenetz, Jane C. Weeks

    Опубліковано 2008
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

    Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma за авторством Brad S. Kahl, Nancy L. Bartlett, John P. Leonard, Ling Chen, Kristen N. Ganjoo, Michael E. Williams, Myron S. Czuczman, Katherine Robinson, Robin Joyce, Richard H. van der Jagt, Bruce D. Cheson

    Опубліковано 2009
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: <i>in vivo</i> evidence of immune activation and antitumour response

    Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: <i>in vivo</i> evidence of immune activat... за авторством Asher Chanan‐Khan, Kasyapa S. Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry Mashtare, Greg Wilding, Kelvin H. Lee, Myron S. Czuczman, Ivan Borrello, Naveen Bangia

    Опубліковано 2011
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review

    The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review за авторством Denise M Oliansky, Myron S. Czuczman, Richard I. Fisher, Frank D. Irwin, Hillard M. Lazarus, James Omel, Julie M. Vose, Steven N. Wolff, Roy B. Jones, Philip L. McCarthy, Theresa Hahn

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  20. 20
    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells за авторством Juan Du, Sandra López‐Vergès, Brandelyn N. Pitcher, Jeffrey L. Johnson, Sin‐Ho Jung, Lili Zhou, Katharine C. Hsu, Myron S. Czuczman, Bruce D. Cheson, Lawrence Kaplan, Lewis L. Lanier, Jeffrey M. Venstrom

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: